You Are Invited

Paradigm Shifts in Early Stage Breast Cancer

The Role of Neoadjuvant and Post-Neoadjuvant Therapies

CONFERENCE CHAIRS
Lajos Pusztai, MD, DPhil
Brian Czerniecki, MD
Eleftherios Mamounas, MD
Ruta Rao, MD

SATURDAY, August 24, 2019
7:50 AM – 3:30 PM
(Sign-in/Breakfast/Exhibits begin at 7:00 AM)

Rush University
1725 West Harrison Street
Searle Conference Center, Brainard Room, Suite 542
Chicago, IL
www.plexuscomm.com/2019bc
Register/Additional Information

AGENDA

Session I — The importance of pathologic complete response
8:00 – 8:20 AM
Brigid Killelea, MD (Yale University): The current landscape of neoadjuvant and adjuvant chemotherapy use in the USA

8:20 – 8:40 AM
Sunil Badve, MD (Indiana U): The prognostic importance of residual cancer burden after neoadjuvant chemotherapy

8:40 – 9:00 AM
Donald Berry, PhD (MDACC): Why survival improvement can be small despite substantial improvement in pathologic complete response rate

9:00 – 9:20 AM
Lajos Pusztai, MD, DPhil (Yale University): Neoadjuvant versus adjuvant chemotherapy

9:20 – 9:30 AM Q & A

9:30 – 9:50 AM
Break/Exhibits

Session II — The role of neoadjuvant therapies in TNBC and HER2+ disease
9:50 – 10:20 AM
William J. Gradishar, MD (Northwestern U): Standard of care neoadjuvant/adjuvant therapies for TNBC, the current NCCN recommendations

10:20 – 10:40 AM
Charles Geyer, MD (VCU Massey): Neoadjuvant therapy of HER2 Positive breast cancer

10:40 – 11:00 AM
Nita Nanda, MD (U Chicago): Innovative combination therapies in the neoadjuvant setting to improve pCR rates the i-SPY2 experience

11:00 – 11:20 AM
Hiroyuki Abe, MD, PhD (U Chicago): Imaging assessment of breast cancer before, during, and after neoadjuvant therapy

11:20 – 11:40 AM
Sunil Badve, MD (Indiana U): Tumor infiltrating lymphocytes and other predictors of response to neoadjuvant chemotherapy

11:40 – 11:50 AM Q & A

11:50 AM – 12:50 PM
Lunch/Exhibits

Session III — The post-neoadjuvant therapies in TNBC and HER2+ breast cancer
12:50 – 1:00 PM
Lajos Pusztai, MD, DPhil (Yale University): Post neoadjuvant treatment options for HER2 positive breast cancer with residual disease

1:00 – 1:20 PM
Eleftherios Mamounas, MD (Orlando Health UF Health Cancer Center): Post neoadjuvant treatment options for HER2 positive breast cancer with residual disease

1:20 – 1:40 PM
Nadine Tung, MD (Beth Israel Deaconess Medical Center): Opportunities to de-escalate care after pathologic complete response in HER2 positive breast cancer

1:40 – 2:00 PM
Brian Czerniecki, MD (Moffitt): Emerging concepts in Immune therapies for patients with residual disease

2:00 – 2:10 PM Q & A

2:10 – 2:30 PM
Break/Exhibits

2:30 – 2:50 PM
Steve Chmura, MD (U Chicago): What is oligometastases and why is NCI doing a Phase 3 trial integrating SBRT into the early M1 disease?

2:50 – 3:10 PM
Henry Kuerer, MD (MDACC): De-escalation of breast and axillary surgery after neoadjuvant systemic therapy

3:10 – 3:20 PM Q&A

3:20 – 3:30 PM Concluding Remarks

This activity will provide 6.0 CME/CE credit hours. Additional info can be found on website.

www.plexuscomm.com/2019bc

In cooperation with and sponsored by:

Yale New Haven Health
Smilow Cancer Hospital

MOFFITT CANCER CENTER

Register/Additional Information

In cooperation with and sponsored by:

Yale New Haven Health
Smilow Cancer Hospital